drugset / Trial / NCT01989936

Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan

NCT01989936

Phase 3 Completed 446 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).

Timeline

Start
1999-01
Primary completion
2000-09
Completion
2000-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Eletriptan Small molecule 40 mg Oral
Subject Eletriptan Small molecule 80 mg Oral

Indications